Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus serotype 3 (DENV-3) viral antigens, primarily the envelope (E) glycoprotein and nonstructural protein 1 (NS1), serve as critical targets for the development of vaccines and therapeutic monoclonal antibodies. The E glycoprotein is the major structural protein on the virion surface, mediating host cell receptor binding and membrane fusion, while NS1 is a secreted glycoprotein essential for viral replication and immune evasion. These antigens are highly immunogenic and elicit serotype-specific neutralizing antibody responses. However, because DENV-3 is genetically and antigenically distinct from the other three dengue serotypes (DENV-1, -2, and -4), targeting these antigens requires careful design to avoid antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies facilitate viral entry into host cells and exacerbate disease severity. Therapeutic strategies targeting DENV-3 antigens include tetravalent live-attenuated vaccines like TAK-003 and CYD-TDV, which incorporate DENV-3 structural proteins, as well as investigational monoclonal antibodies such as VIS513, AV-1, and the highly potent DENV-3-specific antibody 5J7.
Active immunization to elicit protective neutralizing antibodies (vaccines); Passive immunization via direct neutralization of viral envelope proteins to block viral entry and fusion (monoclonal antibodies).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus serotype 3 viral antigens (DENV-3 antigens).